← Back to the library
Published

Epitalon

A synthetic tetrapeptide promoted for telomerase/longevity effects on mostly Russian, largely preclinical evidence; not FDA-approved, in FDA Category 2, and slated for July 2026 PCAC review.

3
Primary sources
Not staged
Evidence stage
Jul 2026
Last reviewed

This page describes where Epitalon has been studied, not what it will do for you. Findings here come largely from animal and cell models and do not establish safety or benefit in humans. Nothing here is medical advice, and Proven Panel sells nothing.

What it is

Epitalon (also spelled epithalon) is a synthetic tetrapeptide derived from research on pineal-gland peptides, studied in a longevity/aging context.S3

Marketed as

Epitalon carries some of the category's most ambitious anti-aging claims — it is promoted for activating telomerase, lengthening telomeres, and slowing aging. These are marketing claims, and among the least substantiated in the field — not established effects.S1S3

Regulatory status (US)

Epitalon is not FDA-approved and holds no approval from major regulators.S1S3 It appears among the peptides in FDA's Category 2 compounding review and is on the agenda for the July 2026 Pharmacy Compounding Advisory Committee.S1S2 In the US it is otherwise treated as a research-use-only compound.S3

Around the world

Epitalon is not an approved medicine in major Western markets; it circulates as a research compound rather than a licensed drug.S3

Evidence

The telomerase and longevity claims rest largely on Russian research and animal data, with limited independently replicated human evidence (see caveat).S3 These claims should be framed as unproven, not established.S3

⚑ Provisional

Epitalon's telomerase/longevity claims rest largely on Russian research and animal data, with limited independently replicated human evidence; they should be treated as unproven, not established. S3

Anti-doping

Epitalon is not a GH secretagogue; its specific anti-doping status should be checked against the current WADA List rather than assumed.S1

Safety

As an unapproved research peptide, Epitalon has little independent long-term human safety data, and use falls outside FDA finished-drug oversight; FDA's general Category 2 concerns (characterization, purity, limited safety information) apply.S1S3

What's changing

The near-term item is the July 2026 PCAC review and any subsequent FDA decision on Epitalon's compounding status.S1S2

Sources

Every reference below is a primary source cited in this entry, drawn from the approved corpus.

  1. 01
  2. 02
  3. 03

Follow this compound

Get an email when FDA / WADA / ClinicalTrials moves on Epitalon.

Follow this

The Panel Brief

What moved in supplement & peptide regulation this week. Free, cited, unsubscribe anytime.

You must be 18 or older to create an account.